Compare · NVST vs RMD
NVST vs RMD
Side-by-side comparison of Envista Holdings Corporation (NVST) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVST and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 6.6x NVST ($4.35B).
- Over the past year, NVST is up 37.1% and RMD is down 22.9% - NVST leads by 59.9 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 2 for NVST).
- RMD has more recent analyst coverage (25 ratings vs 24 for NVST).
- Company
- Envista Holdings Corporation
- ResMed Inc.
- Price
- $26.75-0.83%
- $198.99-1.86%
- Market cap
- $4.35B
- $28.86B
- 1M return
- +8.08%
- +2.60%
- 1Y return
- +37.08%
- -22.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 2
- 7
- Recent ratings
- 24
- 25
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NVST
- BMO Capital Markets initiated coverage on Envista with a new price target
- Envista Schedules Second Quarter 2026 Earnings Call
- Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form SD filed by Envista Holdings Corporation
- Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability
- Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board
- Director Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)
- Director Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)
- Director Raskas Daniel was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)
- Director Huennekens R Scott was granted 12,585 shares, increasing direct ownership by 18% to 82,105 units (SEC Form 4)
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)